Brokerages Set Biohaven Ltd. (NYSE:BHVN) PT at $25.93

Shares of Biohaven Ltd. (NYSE:BHVN) have been assigned a consensus rating of “Moderate Buy” from the eighteen analysts that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, nine have given a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $25.5714.

A number of research analysts have commented on BHVN shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Biohaven in a report on Monday, December 29th. Bank of America cut shares of Biohaven from a “buy” rating to a “neutral” rating and set a $10.00 target price for the company. in a research report on Wednesday, November 5th. Cowen restated a “buy” rating on shares of Biohaven in a research note on Wednesday, November 5th. Citigroup reaffirmed a “buy” rating on shares of Biohaven in a research report on Friday, December 26th. Finally, TD Cowen cut their price objective on shares of Biohaven from $50.00 to $15.00 and set a “buy” rating for the company in a report on Wednesday, November 5th.

Insider Buying and Selling

In related news, Director John W. Childs acquired 3,333,333 shares of the company’s stock in a transaction on Thursday, November 13th. The stock was purchased at an average cost of $7.50 per share, with a total value of $24,999,997.50. Following the acquisition, the director directly owned 5,653,904 shares of the company’s stock, valued at approximately $42,404,280. The trade was a 143.64% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Gregory Bailey bought 400,000 shares of the business’s stock in a transaction dated Thursday, November 13th. The shares were bought at an average price of $7.50 per share, with a total value of $3,000,000.00. Following the completion of the transaction, the director owned 2,020,071 shares in the company, valued at approximately $15,150,532.50. This trade represents a 24.69% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders have acquired 4,416,999 shares of company stock valued at $33,144,833. 16.00% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Wealth Enhancement Advisory Services LLC acquired a new stake in Biohaven during the fourth quarter worth about $441,000. XTX Topco Ltd acquired a new position in shares of Biohaven in the 3rd quarter valued at approximately $955,000. Alyeska Investment Group L.P. bought a new stake in shares of Biohaven during the 3rd quarter worth approximately $3,002,000. Verition Fund Management LLC boosted its position in shares of Biohaven by 19.4% during the 3rd quarter. Verition Fund Management LLC now owns 146,180 shares of the company’s stock worth $2,194,000 after acquiring an additional 23,724 shares in the last quarter. Finally, Quantessence Capital LLC acquired a new stake in shares of Biohaven during the 3rd quarter worth approximately $945,000. Institutional investors and hedge funds own 88.78% of the company’s stock.

Biohaven Stock Down 3.3%

Shares of BHVN opened at $11.36 on Tuesday. The firm has a market cap of $1.20 billion, a P/E ratio of -1.49 and a beta of 1.14. The company has a debt-to-equity ratio of 1.91, a quick ratio of 2.86 and a current ratio of 2.86. Biohaven has a 52 week low of $7.48 and a 52 week high of $44.28. The firm’s 50-day simple moving average is $10.25 and its 200 day simple moving average is $13.35.

Biohaven (NYSE:BHVN) last issued its quarterly earnings data on Monday, November 10th. The company reported ($1.64) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.91) by $0.27. On average, analysts forecast that Biohaven will post -8.9 earnings per share for the current year.

Biohaven Company Profile

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.